AEZ Share Price

Open 3.90 Change Price %
High 4.01 1 Day -0.31 -8.09
Low 3.49 1 Week 0.30 9.32
Close 3.52 1 Month -1.65 -31.91
Volume 75545 1 Year -1.02 -22.47
52 Week High 7.32
52 Week Low 3.18
AEZ Important Levels
Resistance 2 4.00
Resistance 1 3.80
Pivot 3.67
Support 1 3.24
Support 2 3.04
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
BBD-B 2.61 -5.09%
TBE 0.03 0.00%
CCO 14.39 -16.92%
CCO 14.39 -16.92%
CCO 14.39 -16.92%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
IMP 0.08 14.29%
IMP 0.08 14.29%
IMP 0.08 14.29%
ANX 0.08 14.29%
ANX 0.08 14.29%
CET 1.04 14.29%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
CCO 14.39 -16.92%
CCO 14.39 -16.92%
CCO 14.39 -16.92%
CTU-A 0.19 -9.52%
AEZ 3.52 -8.09%
AEZ 3.52 -8.09%
AEZ 3.52 -8.09%
SLR 0.87 -7.45%
SLR 0.87 -7.45%
More..

AEterna Zentaris, Inc. (TSE: AEZ)

AEZ Technical Analysis 5
As on 18th Jan 2017 AEZ Share Price closed @ 3.52 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.65 & Strong Sell for SHORT-TERM with Stoploss of 4.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEZ Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AEZ Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aezsinc.com
AEZ Address
AEZ
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Canada
Phone: 418-652-8525
Fax: 418-948-9191
Interactive Technical Analysis Chart AEterna Zentaris, Inc. ( AEZ TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AEterna Zentaris, Inc.
AEZ Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.